Director/PDMR Shareholding

19 February 2013

e-Therapeutics plc ("e-Therapeutics" or the "Company")

Director/PDMR Shareholding

The Company received notification on 18 February 2013 that Novotech Investment Limited (NIL), a company of which Professor Malcolm Young (CEO) is a director and in which he has options to subscribe for ordinary shares, had sold 50,000 ordinary shares in e-Therapeutics plc at GBP0.31 per share on 18 February 2013. Professor Young had no knowledge of the proposed sale and, as one of three directors in NIL, had no ability by himself to prevent NIL from selling the shares. It is understood that NIL has disposed of the shares to enable NIL to discharge its obligations to third parties.

Following the sale, Professor Young's indirect holding in the Company has been reduced by 14,920 shares.

This has resulted in Professor Young's total beneficial interest in the Company now being 21,022,742 shares, representing 15.21% of the total issued share capital of the company. However, Professor Young's direct beneficial interest in the Company remains unchanged at 20,644,958 shares, representing 14.94% of the total issued share capital of the Company (of which 10,334,717 shares are held by Professor Young and 10,310,241 shares are held by Professor Young's wife).

-Ends-

For more information, please contact:

e-Therapeutics plc

Daniel Elger

Tel: +44 (0) 79 0991 5068

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Corporate Finance: Fred Walsh / Grishma Patel

Corporate Broking: Hannah Woodley

Tel: +44 (0) 20 7886 2500

www.panmure.com